Clinical trials: Hypertension, Portal
Cystic Fibrosis, Portal Hypertension
Portal Hypertension and Systemic Endothelial Function
Cystic fibrosis can affect organs other than the lungs. Liver disease affects about 30% of patients: its main manifestation is the development of portal hypertension (PHT).
- Trial name
- ENDOTH-MUCO (NCT02850692)
- Testing
- measure of endothelial function, Blood sample, Hepatic elastography
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hopital Foch
Portal Hypertension, Liver Diseases
Hemodynamic Alterations in Liver Cirrhosis Validated by Non-invasive MR Compared to Invasive Assessment
Liver cirrhosis is a chronic disease characterized by a progressive accumulation of fibrosis, loss of liver function and portal hypertension leading to several hemodynamic changes.The exact pathophysiological mechanisms causing…
- Conditions
- Portal Hypertension, Liver Diseases, Liver Cirrhoses, Cirrhosis
- Trial name
- NCT03443934
- Where
- Denmark
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Esophageal Varices in Cirrhosis of the Liver
Radiomics-based Surrogate of Endoscopy (rEndosc) (CHESS1703)
Esophageal varices (EVs) resulting from portal hypertension are a prevalent complication of cirrhosis with a high mortality when variceal hemorrhage (VH) occurs.
- Trial name
- rEndosc (NCT03373123)
- Testing
- Endoscopy, CTA
- Where
- 9 sites in China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Clinically Significant Portal Hypertension
The Impact of Carvedilol Posology on Clinically Significant Portal Hypertension
Carvedilol has emerged as the preferred non-selective β-blocker (NSBB) for treating portal hypertension. However, there is still a debate in dosing regimen, specially regarding dose interval, with a potential lower bioavalability…
- Trial name
- NCT06015373
- Testing
- supress the night dose of carvedilol
- Where
- Portugal
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Centro Hospitalar De São João, E.P.E.
Cirrhosis, Liver, Portal Hypertension
LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study
The LIVE-SMART supplementary study will assess social determinants of health (income, education, neighborhood deprivation), financial burden (out-of-pocket costs, productivity loss), financial distress (patient and…
- Trial name
- LiveSMART (NCT07140120)
- Where
- 3 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Portal Hypertension, Clinically Significant Portal Hypertension
Assessment of Portal Hypertension With Multiparametric MRI
The purpose of this study is to determine whether new multiparametric magnetic resonance imaging (MRI) methods (including diffusion-weighted MRI, dynamic contrast-enhanced MRI, MR elastography and phase-contrast imaging) can be…
- Trial name
- NCT03436550
- Testing
- mpMRI, ARFI US
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Esophageal and Gastric Varices
Comparison of Endoscopic Band Ligation Plus 24-hour Versus 72-hour Terlipressin Therapy
In the Western world, liver cirrhosis is a significant issue. Acute variceal bleeding (AVB) is a considerable complication of cirrhosis associated with high mortality.
- Trial name
- NCT05331768
- Testing
- banding ligation plus terlipressin infusion
- Where
- Mexico
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Instituto Mexicano del Seguro Social
Cirrhosis, Compensated Cirrhosis
The Use of Endoscopic Ultrasound-Guided Portal Pressure Measurements to Guide Beta-Blocker Therapy in Patients With Compensated Cirrhosis
This pilot study to determine the feasibility of EUS-Portal Pressure Measurements to guide Beta-Blocker Therapy in patients with compensated cirrhosis .The study will be a prospective tandem controlled trial consisting of 30…
- Conditions
- Cirrhosis, Compensated Cirrhosis, Portal Hypertension
- Trial name
- NCT05357599
- Testing
- EUS
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Portal Hypertension, Liver Cirrhosis
Laparoscopic Versus Open Devascularization for Portal Hypertension, a Randomized Controlled Trial
Many patients with portal hypertension require surgical treatment each year,and Hassab's operation, or esophagogastric devascularization and splenectomy, is an elective procedure.
- Trial name
- NCT02178319
- Testing
- open surgical procedure, laparoscopic surgical procedure
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Cirrhosis, Liver, Portal Hypertension
Two-dimensional Shear Wave Elastography for Assessment of Cirrhosis and Portal Hypertension
Exploring and establishing new non-invasive risk stratification techniques for portal hypertension based on E imaging technology for measuring liver and spleen stiffness is an urgent need in this field of research.
- Trial name
- NCT06358092
- Testing
- Hepatic venous pressure gradient, Two-Dimensional Shear Wave Elastography
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Cirrhosis
Spleen Stiffness Measurement With FibroScan
FibroScan® (Echosens, Paris, France) is an active non implantable medical device marketed in Europe since December 2003 and is currently used in many countries.
- Trial name
- NCT02180113
- Testing
- Fibroscan® examination
- Where
- 7 sites in France, Italy and 2 more
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Echosens
Coagulation Disorder, Cirrhosis, Liver
ADAMTS-13 and Von Willebrand Factor Levels and Activities in Children With Cirrhosis and/or Portal Hypertension
Hemostasis-related disorders are common in cirrhosis and portal hypertension. However, it is not known whether the net effect of changes in hemostasis in the sense of predisposition to hemorrhagic or thrombotic state.
- Trial name
- NCT04267406
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Ataturk University
Hypertension, Atherosclerosis
Age-Related Changes in Body Composition
Background: Advancing age is associated with greater risk of heart disease. High blood pressure and hardening of the arteries also have more complications with age.
- Trial name
- NCT01517113
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Liver Cirrhosis, Portal Hypertension
Microparticles in Cirrhosis and Portal Hypertension
research on interactions between portal hypertension and microparticles
- Trial name
- MicroCir (NCT02859610)
- Testing
- research on interactions between portal hypertension and microparticles
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Liver Cirrhosis, Portal Hypertension
Evaluation of Probiotics in the Treatment of Portal Hypertension
This study is to evaluate the role of probiotics in the treatment of portal hypertension. In particular the role of probiotics on gut microbiota in liver cirrhosis patients will be studied and compared with cytokines and other…
- Conditions
- Liver Cirrhosis, Portal Hypertension, Encephalopathy
- Trial name
- NCT00831337
- Testing
- VSL3
- Where
- Poland
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pomeranian Medical University Szczecin
Portal Hypertension
Clinical,Endoscopic and Radiological Assessment of Portal Hypertension in Children With Chronic Liver Diseases
Portal hypertension is a significant cause of morbidity and mortality in children with chronic liver disease and portal vein obstruction.
- Trial name
- NCT06097715
- Testing
- upper gastrointestinal endoscopy, 1- Complete blood count 2- Coagulation profile
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sohag University
Liver Cirrhosis, Acute-On-Chronic Liver Failure
Characterization and Pathogenesis of ACLF
This single-center prospective observational study aims at characterization of pathogenesis of ACLF. There will be three different cohorts investigated with the main endpoint mortality in these groups. 1.
- Conditions
- Liver Cirrhosis, Acute-On-Chronic Liver Failure, Portal Hypertension
- Trial name
- ACLF-I (NCT04975490)
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Johann Wolfgang Goethe University Hospital
Essential Hypertension, Hepatic Impairment
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers
To compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in hepatic impairment patients and healthy volunteers
- Trial name
- NCT01146938
- Testing
- fimasartan
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Portal Hypertension, Chronic Liver Disease
EUS vs TJ for Liver Biopsy and Portal Pressure Gradient Measurement
This study will directly compare the endoscopic ultrasound guided approach to obtain adequate liver biopsies and portal pressure gradient measurements to the current standard of care which uses the transjugular approach.
- Conditions
- Portal Hypertension, Chronic Liver Disease, Cirrhosis
- Trial name
- NCT05118308
- Testing
- Transjugular hepatic venous pressure gradient measurement with liver biopsy, Endoscopic ultrasound portal pressure gradient measurement with liver biopsy
- Where
- Canada
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Systolic and Diastolic Blood Pressure Levels, Uric Acid Levels
Hyperuricemia on Hypertension and Metabolic Syndrome
The purpose of this study is to evaluate the influence of hyperuricemia treatment compared with placebo on participants with high risk of hypertension and metabolic syndrome.
- Conditions
- Systolic and Diastolic Blood Pressure Levels, Uric Acid Levels, Metabolic Syndrome Parameters, Hepatic Enzymes
- Trial name
- NCT01157936
- Testing
- Allopurinol
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez